Can Bacteria Resist Antimicrobial Peptides?
Antimicrobial Peptides as Alternatives to Antibiotics
14 AMPs tested
In a systematic evolutionary analysis, certain AMPs like tachyplesin II and cecropin P1 showed resistance levels so low they were effectively negligible, even after prolonged laboratory evolution.
Spohn et al., Nature Communications, 2019
Spohn et al., Nature Communications, 2019
View as imageBacteria have coexisted with antimicrobial peptides (AMPs) for hundreds of millions of years. Unlike conventional antibiotics, which typically target a single molecular pathway, AMPs attack the bacterial cell membrane itself, a structure so fundamental that altering it often comes at a steep fitness cost. This distinction is why antimicrobial peptide resistance evolves far more slowly than antibiotic resistance, but "slowly" does not mean "never." Bacteria have developed a sophisticated toolkit of resistance strategies, from remodeling their surface charge to secreting enzymes that chew up peptides before they reach the membrane. Understanding these mechanisms is essential for anyone evaluating whether AMPs can realistically replace or supplement antibiotics in clinical practice.
A 2016 review in Philosophical Transactions of the Royal Society cataloged the full spectrum of bacterial AMP resistance strategies across both Gram-positive and Gram-negative species, identifying six primary categories: surface repulsion, membrane charge alteration, proteolytic degradation, efflux pump removal, biofilm formation, and extracellular sequestration.[1] Each mechanism targets a different stage of the AMP killing process, from initial binding to membrane insertion to intracellular damage.
Key Takeaways
- A 2019 Nature Communications study testing 14 AMPs found that resistance to tachyplesin II and cecropin P1 was effectively negligible even after prolonged evolution in E. coli (Spohn et al., 2019)
- The mobile colistin resistance gene MCR-1 increased E. coli resistance to host AMPs by an average of 62%, raising concerns about cross-resistance between therapeutic and innate immune peptides (Jangir et al., 2023)
- S. aureus uses the MprF enzyme to flip membrane charge from negative to positive, repelling cationic AMPs; mutants lacking MprF are dramatically more susceptible to killing (Andra et al., 2011)
- Salmonella's PhoP-PhoQ two-component system regulates at least two separate gene networks for AMP resistance, linking virulence directly to peptide defense (Gunn and Miller, 1996)
- Bacteria in biofilms tolerate up to 1,000-fold higher AMP concentrations than their free-floating counterparts (Joo et al., 2016)
- Simple physicochemical features of an AMP, specifically its charge, hydrophobicity, and amphipathicity, predict how readily bacteria can evolve resistance to it (Spohn et al., 2019)
The Short Answer: Yes, But With Major Caveats
Bacteria can develop resistance to antimicrobial peptides. This is not a theoretical concern; it has been demonstrated repeatedly in laboratory evolution experiments and observed in clinical isolates.[1] However, the nature of AMP resistance differs from antibiotic resistance in three critical ways.
First, the rate of resistance emergence is dramatically slower. Antibiotics can become clinically useless within years of their introduction. AMPs have been part of the innate immune system for over 500 million years, and while bacteria have evolved countermeasures, they have not rendered these peptides obsolete.[8] The reason lies in the target: AMPs generally attack the lipid bilayer rather than a single protein, and changing the fundamental composition of a cell membrane is biologically expensive.
Second, the magnitude of resistance is typically lower. When Spohn et al. systematically evolved E. coli against 14 chemically diverse AMPs and 12 conventional antibiotics, they found that resistance levels achieved through point mutations and gene amplification were "very low" for certain AMPs, particularly tachyplesin II and cecropin P1.[2] Antibiotic-resistant bacteria displayed no cross-resistance to these hard-to-resist peptides. Soil metagenomics confirmed the pattern: genomic fragments from diverse soil bacteria, which serve as a natural reservoir of resistance genes, conferred no detectable resistance when introduced on plasmids.
Third, resistance to one AMP does not automatically confer resistance to all AMPs. The Spohn study found that simple physicochemical features, specifically charge, hydrophobicity, and the degree of amphipathic structure, dictate a bacterium's propensity to evolve resistance.[2] AMPs with certain structural profiles appear intrinsically harder to resist, providing a rational basis for designing next-generation therapeutics.
How Bacteria Remodel Their Surfaces to Repel AMPs
Most cationic AMPs rely on electrostatic attraction to negatively charged bacterial membranes as the first step in their killing mechanism. Bacteria counteract this by reducing the net negative charge on their surfaces.
Membrane Charge Modification via MprF
In Gram-positive bacteria like Staphylococcus aureus, the multiple peptide resistance factor (MprF) enzyme catalyzes the addition of L-lysine to membrane phosphatidylglycerol (PG), converting its net charge from -1 to +1.[5] Andra et al. demonstrated that S. aureus mutants lacking a functional mprF gene were dramatically more susceptible to antimicrobial peptides including NK-2 (a mammalian NK-lysin fragment), arenicin-1 (a lugworm peptide), and melittin (from bee venom). The biophysical data showed that lysyl-PG in the membrane reduced peptide binding, insertion, and permeabilization, though the degree of modulation was unique for each peptide tested.[5]
Lipid A Modifications in Gram-Negative Bacteria
Gram-negative bacteria take a different approach. They modify the lipid A component of their lipopolysaccharide (LPS) outer membrane, adding positively charged groups like 4-amino-4-deoxy-L-arabinose or phosphoethanolamine to neutralize the negative charge.[1] These modifications are tightly regulated by environmental sensing systems, most famously the PhoP-PhoQ and PmrA-PmrB two-component systems in Salmonella.
D-Alanylation of Teichoic Acids
Gram-positive bacteria also modify their cell wall teichoic acids by adding D-alanine residues through the dlt operon. This reduces the negative charge of the cell wall, creating an electrostatic shield that repels cationic peptides before they even reach the cytoplasmic membrane.[1]
The PhoP-PhoQ Regulatory Cascade
The two-component regulatory system PhoP-PhoQ is one of the best-studied AMP resistance regulators and provides a window into how bacteria sense and respond to peptide threats. In Salmonella typhimurium, PhoQ is a sensor kinase embedded in the inner membrane that detects the presence of cationic AMPs and low Mg2+ concentrations. When activated, it phosphorylates the transcriptional regulator PhoP, which then turns on dozens of genes required for survival inside macrophages and resistance to host defense peptides.
Gunn and Miller showed in 1996 that PhoP-PhoQ activates transcription of the pmrAB operon, a second two-component system specifically involved in resistance to polymyxin, azurocidin, bactericidal/permeability-increasing protein (BPI), protamine, and polylysine.[4] Their work revealed that PhoP regulates at least two separate gene networks for AMP resistance, creating a layered defense system activated by environmental cues.
Shprung et al. later investigated which AMP properties trigger PhoP-PhoQ activation by testing a broad repertoire of peptides differing in length, charge, and hydrophobicity.[6] They found a strong correlation between an AMP's positive charge, hydrophobicity, and amphipathicity and its potency to activate the system. Wild-type bacteria were more resistant to AMPs that strongly activated PhoP-PhoQ, confirming that the regulatory system provides meaningful protection. However, the study also identified a subset of AMPs that were equally toxic to wild-type and mutant bacteria, meaning some peptides can overcome PhoP-PhoQ-mediated resistance entirely.[6]
Proteases, Trapping Proteins, and Efflux Pumps
Beyond surface remodeling, bacteria deploy active mechanisms to neutralize AMPs after they arrive.
Proteolytic Degradation
Both Gram-positive and Gram-negative bacteria secrete proteases that cleave and inactivate AMPs. S. aureus secretes metalloproteinases like aureolysin and the serine endopeptidase SepA. Gram-negative bacteria use omptins, outer membrane proteases that specifically degrade alpha-helical AMPs.[1] The PgtE outer membrane protease of Salmonella, for example, is itself regulated by the PhoP-PhoQ system, linking protease production directly to AMP detection.
Extracellular Trapping and Sequestration
S. aureus also secretes staphylokinase (Sak), a protein that binds to and neutralizes specific AMPs. Nguyen and Vogel demonstrated that the truncated form of staphylokinase (SakDeltaN10), which occurs naturally through in vivo processing, has improved affinity for AMPs including the murine cathelicidin mCRAMP and bovine lactoferricin.[7] They identified two distinct AMP binding surfaces on the protein, showing that staphylokinase functions as a decoy that intercepts peptides before they reach the membrane. Earlier work estimated that staphylokinase can reduce the activity of AMPs by up to 80%.[1]
Capsular polysaccharides serve a similar trapping function. Bacteria that produce thick capsules can physically sequester AMPs, reducing the effective concentration that reaches the cell surface.[8]
Efflux Pumps
RND-family and ABC transporter efflux pumps actively export AMPs from the bacterial cell. These pumps are not AMP-specific; they often provide cross-resistance to multiple antimicrobial agents simultaneously.[1] In Gram-negative bacteria, the MtrCDE efflux system in Neisseria gonorrhoeae exports LL-37, protegrins, and other cationic AMPs.
Biofilms: The Ultimate Resistance Fortress
Bacteria growing in biofilms exhibit up to 1,000-fold higher resistance to both antibiotics and AMPs compared to their planktonic counterparts.[1] The exopolysaccharide matrix acts as a physical barrier that slows AMP diffusion, provides electrostatic sequestration, and creates microenvironments with altered pH and ionic conditions that reduce AMP activity. This is one of the reasons biofilm infections remain so difficult to treat even with next-generation antimicrobials.
Biofilm resistance is particularly concerning because roughly 80% of chronic bacterial infections involve biofilms. Even AMPs specifically designed for high membrane-disrupting activity lose much of their potency when bacteria are growing in a biofilm matrix rather than floating freely.
The Colistin-MCR Warning: When Therapeutic AMPs Backfire
One of the most alarming developments in AMP resistance comes from the mobile colistin resistance (MCR) gene family. Colistin is a polymyxin-class AMP used as a last-resort antibiotic for multidrug-resistant Gram-negative infections. The MCR-1 gene, which encodes an enzyme that modifies lipid A with phosphoethanolamine, was first identified in 2015 on a transferable plasmid in E. coli from Chinese livestock.
Jangir et al. published a landmark study in eLife in 2023 demonstrating that MCR does far more than confer colistin resistance.[3] The MCR-1 gene increased E. coli resistance to key human and animal host AMPs by an average of 62%. It also promoted bacterial growth in human serum and increased virulence in a Galleria mellonella infection model. The implications are stark: the agricultural use of colistin selected for a resistance gene that also compromises the innate immune response of humans and animals.
This finding suggests that MCR may persist in bacterial populations even if colistin use is completely withdrawn, because the gene provides a selective advantage against the host's own antimicrobial peptides.[3] It is a cautionary example of how therapeutic AMP use can accidentally select for resistance to the innate immune system, with consequences that extend well beyond the clinic.
Why AMP Resistance Still Differs From Antibiotic Resistance
Despite this extensive toolkit of bacterial countermeasures, AMP resistance remains fundamentally different from antibiotic resistance in several respects that matter for therapeutic development.
The co-evolutionary arms race between AMPs and bacteria has been running for hundreds of millions of years. During that time, bacteria have not rendered AMPs obsolete the way they have rendered individual antibiotics useless within decades.[8] Kumaresan et al. noted in their 2024 review that non-pathogenic commensal bacteria actively upregulate host defensin expression as a strategy to outcompete resistant pathogens, creating a dynamic equilibrium rather than a one-way resistance escalation.
The Spohn et al. evolutionary analysis provides the strongest evidence for optimism. When they tested resistance evolution against 14 AMPs in parallel with 12 antibiotics, certain AMPs showed effectively negligible resistance development.[2] The key finding was that AMPs' physicochemical properties predict resistance potential: peptides with specific combinations of charge, hydrophobicity, and structural rigidity are intrinsically harder for bacteria to resist. This provides a rational design framework, not just for selecting existing AMPs but for engineering new ones optimized for low resistance potential.
The trade-off between resistance and fitness is another critical factor. Many AMP resistance mechanisms, particularly membrane charge modifications, impose a metabolic cost that reduces bacterial growth rate and virulence in the absence of AMP pressure.[1] This fitness penalty means that AMP-resistant mutants are often outcompeted by susceptible bacteria once the selective pressure is removed.
What This Means for AMP Therapeutic Development
The evidence on AMP resistance supports cautious optimism rather than either uncritical enthusiasm or fatalism. Several principles emerge from the research:
AMP design should prioritize low-resistance-potential physicochemical profiles. The Spohn et al. framework for predicting resistance evolution based on peptide properties is directly actionable for drug development programs.[2]
Combination approaches pairing AMPs with conventional antibiotics may suppress resistance emergence in both drug classes simultaneously. When AMPs compromise membrane integrity, they can potentiate antibiotic entry into bacterial cells, potentially lowering the effective dose and reducing selection pressure for resistance to either agent.
Clinical deployment should learn from the colistin lesson. The Jangir et al. findings make clear that agricultural and clinical use of AMP-class drugs must account for potential cross-resistance to innate immune peptides.[3] Surveillance programs should monitor not just clinical resistance levels but also resistance to host defense peptides in circulating bacterial populations.
The MRSA problem illustrates the potential intersection of AMP resistance with existing antibiotic resistance. S. aureus strains that are already methicillin-resistant may have co-selected for enhanced MprF activity or other AMP resistance mechanisms, creating a compounded challenge.
The Bottom Line
Bacteria can and do resist antimicrobial peptides through membrane remodeling, proteolytic degradation, efflux pumps, biofilm formation, and extracellular sequestration. However, resistance evolves far more slowly than antibiotic resistance, certain AMPs show effectively negligible resistance development in evolutionary experiments, and resistance mechanisms often impose significant fitness costs. The mobile colistin resistance gene MCR-1 represents a serious warning about cross-resistance between therapeutic and innate immune AMPs. Rational AMP design based on physicochemical properties that predict low resistance potential offers a path forward.